Alembic Pharmaceuticals Ltd: History, Latest Updates, Milestones, Subsidiaries and Share Price
INTRODUCTION
Alembic Pharmaceuticals Ltd is one of India’s leading pharmaceutical companies with a rich history spanning over a century. Known for its innovation-driven approach, the company has played a significant role in the development and manufacturing of high-quality generic and specialty medicines. Over the years, Alembic Pharmaceuticals has achieved several milestones, expanded its global footprint, and established a strong presence in both domestic and international markets. Investors closely track Alembic Ltd share price as the company continues to grow through strategic expansions, new product launches, and regulatory approvals. In this article, we explore the history, key updates, milestones, subsidiaries, and share price trends of Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Ltd moves in 2025:
US FDA Approval: Alembic Pharmaceuticals' Vadodara plant received a Voluntary Action Indicated (VAI) status from the US FDA, signifying compliance with manufacturing standards.
Financial Performance: In Q3 FY25, the company reported a 23% year-over-year decline in net profit to Rs. 138.4 crore, despite a 3.81% increase in consolidated net sales to Rs. 1,692.74 crore.
Share Price Movement: As of October 9, 2025, Alembic Ltd's share price is recorded at Rs. 928.20.
Regulatory Compliance: The company's Vadodara plant received a Voluntary Action Indicated (VAI) status from the US FDA, indicating compliance with manufacturing standards.It reinforced confidence among investors monitoring Alembic Ltd share price and its regulatory track record.
Evolution of Alembic Pharmaceuticals Ltd: From Past to Present:
Past:
- Established in 1907 as Alembic Chemical Works Company Limited, Alembic Pharmaceuticals Ltd. started its operations in Vadodara, Gujarat, with an emphasis on manufacturing tinctures and alcohol. Over the decades, the company expanded its portfolio to include cough syrups, vitamins, tonics, and sulfa drugs. A significant milestone was achieved in 1961 with the inauguration of a dedicated penicillin manufacturing plant by then-Prime Minister Lal Bahadur Shastri. In 1971, Alembic pioneered the production of erythromycin in India, launching the 'Althrocin' brand, which became the nation's top-selling erythromycin by 1997. The company's commitment to quality was further solidified in 2000 when its Vadodara facility received ISO 14000 certification.
Present:
- Today, Alembic Pharmaceuticals Ltd. stands as a prominent Indian multinational pharmaceutical company with a global presence. Headquartered in Vadodara, the company operates state-of-the-art manufacturing facilities in Panelav, Karakhadi, and Sikkim, producing a diverse range of pharmaceutical products, including branded and generic formulations. Alembic has made significant investments in research and development, with two dedicated R&D centers focusing on innovative projects, particularly for the U.S. market. The company's shares are publicly traded on the Bombay Stock Exchange and the National Stock Exchange of India, reflecting its robust financial standing and commitment to delivering high-quality healthcare solutions worldwide.
| Name | Alembic Pharmaceuticals Ltd. |
| Founded year | 1907 |
| Chairman | Chirayu Amin (Chairman) Pranav Amin (Managing Director) Shaunak Amin (Managing Director) |
| Headquarters | Vadodara, Gujarat, India |
| Sector | Pharmaceuticals |
| Subsidiary | Aleor Dermaceuticals Limited Alnova Pharmaceuticals SA Alembic Pharmaceuticals, Inc. |
| Nse code | APPLTD |
| Bse code | 533573 |
Timeline of Alembic Pharmaceuticals Ltd :
| Year | Milestone Achieved |
| 1907 | Began operations in Vadodara, manufacturing tinctures and alcohol. |
| 1940 | Expanded product range to include cough syrups, vitamins, tonics, and sulphur-based medicines. |
| 1961 | Established a Penicillin production plant, inaugurated in the presence of Lal Bahadur Shastri. |
| 1967 | Started large-scale production of Vitamin B12. |
| 1971 | Became the first Indian company to manufacture Erythromycin. |
| 1972 | Introduced Althrocin, an Erythromycin-based antibiotic. |
| 1997 | Althrocin emerged as a leading pharmaceutical brand in India. |
| 1999 | Entered synthetic and organic API production. |
| 2000 | Vadodara facilities received ISO 14000 certification. |
| 2001 | Commenced production of Cephalosporin C. |
| 2007 | Acquired Dabur Pharma Ltd.’s non-oncology business. |
| 2009 | Strengthened focus on chronic therapies with specialized marketing divisions. |
| 2011 | Separated from the Alembic Group, establishing Alembic Pharmaceuticals Ltd. as an independent entity. |
| 2012 | Ventured into dermatology with the launch of eight new products in India. |
| 2013 | Entered the international market by initiating NDA filings in the EU, Australia, and Brazil with a strategic partner. |
| 2015 | Launched Aripiprazole and set up a direct marketing presence in the US. |
| 2016 | Formed Aleor Dermaceutical Limited in partnership with Orbicular to develop dermatology products for global markets. |
| 2017 | Opened an Oncology manufacturing unit, inaugurated by Gujarat CM Vijay Rupani; acquired Orit Laboratories LLC in the USA. |
| 2018 | Aleor’s dermatology facility received FDA approval. |
| 2019 | Oncology oral solid manufacturing facility gained regulatory approval; entered a strategic joint venture for expansion into China. |
| 2020 | Crossed US$ 250 million in sales in the US market. |
Inside Alembic Pharmaceuticals Ltd:
Alembic Pharmaceuticals Ltd
Corporate actions:
As of today, October 9, 2025, Alembic Pharmaceuticals Ltd. has declared 15 dividends since July 31, 2012. In the past 12 months, the company distributed an equity dividend of Rs. 11.00 per share. At the current Alembic Ltd share price of Rs. 928.20 (as of October 9, 2025), the dividend yield stands at approximately 1.18%. The most recent dividend of Rs. 11.00 per share was declared as a final dividend, with the ex-date and record date set for July 15, 2024, applicable to all equity shareholders.
Main News:
- Feb 2025: Alembic Pharmaceuticals Ltd reported a decline in financial performance for Q3 FY25. Sales dropped to Rs. 14,060.90 million, compared to Rs. 15,883.90 million in the same quarter last year. Net profit fell 63.21%, reaching Rs. 858.10 million from Rs. 2,332.40 million in the previous quarter. Operating profit also decreased to Rs. 1,952.90 million, down from Rs. 3,404.40 million in Q3 FY24. The announcement was made in February 2025.
- Jan 2025: Alembic Pharmaceuticals received USFDA approval for Brexpiprazole Tablets (0.25 mg to 4 mg), strengthening its U.S. portfolio.
- Dec 2024: Alembic Pharmaceuticals secured USFDA approval for Divalproex Sodium Delayed-Release Capsules (125 mg), a generic version of Depakote Sprinkle Capsules.
- Alembic Pharmaceuticals successfully completed the ANVISA GMP audit for its API-II facility in Panelav, covering 8 APIs. The inspection took place from September 16 to 20, 2024.
Alnova Pharmaceuticals SA
Main News: On December 6, 2024, Alembic Pharmaceuticals Ltd. announced the dissolution of six non-operational step-down subsidiaries: Okner Realty LLC, Alembic Labs LLC, Alnova Pharmaceuticals SA, Dahlia Therapeutics SA, Genius LLC, and Alembic Mami SpA. This action was disclosed under regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations.
Current Alembic Ltd Stock Price Live NSE:
| COMPANY NAME | SECTOR | SHARE PRICE LINK |
Alembic Pharmaceuticals Ltd
| Healthcare | Alembic Limited Share Price Today live |
Achievements and Milestones:
- Climate Action Awards (2024) – Awarded the Silver Award at the Times Now Global Sustainability Alliance SDG 6th Edition Summit for the Best Climate Action Project.
- International Safety Merit Award (2024) – Recognized by the British Safety Council for excellence in health and safety management.
- Indian Social Impact Awards (2022-23) – Alembic CSR Foundation received the 'Public Health Program Initiative of the Year' award for its Suposhan initiative aimed at combating malnutrition and anemia in 26 villages.
- Great Place to Work Certification – Recognized for its high-trust, high-performance workplace culture and ranked among the top 10 pharmaceutical companies in its category.
- National Awards – Secured the 2nd runner-up position for outstanding learning and development initiatives at the SHRM Event.
- SHRM Award – Honored for having the "Best HR Practice in Healthcare" at the 7th edition of the National Awards for Excellence in Healthcare.
CONCLUSION
In conclusion, Alembic Pharmaceuticals Ltd has cemented its position as a leading player in the pharmaceutical industry with a legacy of innovation, strategic expansion, and regulatory excellence. From its historic milestones to recent achievements in sustainability, safety, and corporate responsibility, the company continues to evolve and strengthen its global footprint. As Alembic Pharma stock remains closely watched by investors, the company's focus on research, product development, and operational growth reinforces its long-term potential in the healthcare sector.
To gain more information on Alembic Pharma stock price, the latest news, and stock analysis, visit Enrich Money. Enrich Money provides a free demat account with no annual charges and it's the best trading app for beginners in India.
Frequently Asked Questions:
Where can I find real-time updates on the Alembic ltd share price?
Explore the latest Alembic Ltd share price and real-time updates on Enrich Money's stock analysis page here.
What has been the peak Alembic ltd share price in the last 52 weeks?
52 Week's highest Alembic ltd share price is Rs 1,303.90, while 52 Week's lowest Alembic Ltd share price is Rs 725.20
What is the latest financial performance of Alembic Pharmaceuticals Ltd?
In Q3 FY25, Alembic Pharmaceuticals Ltd reported a 23% year-over-year decline in net profit, reducing it to Rs. 138.4 crore. However, consolidated net sales rose by 3.81% to Rs. 1,692.74 crore, influencing Alembic Ltd share price movements in the stock market.
How has Alembic Ltd share price performed in 2025?
As of October 9, 2025, Alembic Ltd share price stands at Rs. 928.20. The stock has shown steady performance throughout the year, supported by the company’s consistent regulatory approvals and ongoing global expansion initiatives, which continue to boost investor confidence.
What is the dividend history of Alembic Pharmaceuticals Ltd?
As of today, October 9, 2025, Alembic Pharmaceuticals Ltd. has declared 15 dividends since July 31, 2012. In the last 12 months, the company announced an equity dividend of Rs. 11.00 per share. At the current Alembic Ltd share price of Rs. 928.20, the dividend yield stands at approximately 1.18%. The most recent dividend of Rs. 11.00 per share was declared as a final dividend, with the ex-date and record date on July 15, 2024.
Is Alembic Ltd share price expected to rise in the near future?
Market analysts track Alembic Ltd share price based on financial performance, regulatory developments, and market conditions to predict future trends. However, stock performance is subject to market risks.
Check our ORCA app to analyze stocks' performance:
- Alembic Pharmaceuticals Share Price
- Alembic Pharmaceuticals Technical Analysis
- Alembic Pharmaceuticals Future Price
- Alembic Pharmaceuticals Financial Statements
- Alembic Pharmaceuticals Shareholding Pattern
- Alembic Pharmaceuticals Latest Corporate News
- Alembic Pharmaceuticals Stock/Company Overview
Disclaimer: This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.
